Company Profile

Neuropathix, Inc. is a biopharmaceutical company. It is focused on discovering, developing, and commercializing novel therapeutics from its proprietary synthetic cannabinoid derivative platform that are potentially useful for a range of inflammatory and neuropathic pain-related diseases. Its product candidates include KLS-13019 and KLS-13023. KLS-13019 can control mechanical sensitivity and inflammation associated with chemotherapy-induced peripheral neuropathy (CIPN) in the absence of tolerance development and also reduce opioid craving behavior. KLS-13023 is a drug candidate that includes synthetic cannabidiol (CBD) formulated in a gel capsule designed for potential use in humans. Its drug discovery platform potentially treats neurological and oxidative stress-related disorders, such as overt hepatic encephalopathy (OHE), chronic traumatic encephalopathy (CTE), and CIPN, with current good manufacturing practices (cGMP) pharmaceutical grade semi-synthetic and synthetic cannabinoids.

Employees

Sector

Biotechnology & Medical Research

More about the company

11-18	Neuropathix, Inc. announced a financing transaction	CI
23/05/22	Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
15/04/22	Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
15/04/22	Neuropathix, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/03/22	Neuropathix, Inc. announced that it has received $0.15 million in funding	CI
12/11/21	Neuropathix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
12/08/21	Neuropathix, Inc. Appoints Michael Ropacki to its Scientific Advisory Board	CI
06/08/21	Neuropathix, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
13/05/21	Neuropathix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
30/03/21	Neuropathix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
10/02/21	Neuropathix, Inc. announced that it has received $1.2075 million in funding from Lyons Capital, LLC	CI
12/01/21	Neuropathix, Inc. Appoints Daniel Richman to Board of Advisors	CI
12/11/20	Neuropathix, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI

23/05/22	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
25/04/22	Neuropathix : OTC Certification - Neuropathix, Inc. - FYE 2021	PU
15/04/22	NEUROPATHIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
25/03/22	NEUROPATHIX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
12/11/21	NEUROPATHIX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ

Manager	Title	Age	Since
Dean Petkanas CEO	Chief Executive Officer	47	25/07/2018
William Kinney CTO	Chief Tech/Sci/R&D Officer	68	25/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/5/22 A	Dean Petkanas	Sell	Chief Executive Officer	180,000	0.1981%
1/5/22 A	Dean Petkanas	Sell	Chief Executive Officer	800,000	0.8803%
1/5/22 A	Dean Petkanas	Sell	Chief Executive Officer	720,000	0.7923%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUROPATHIX, INC.	-.--%	-.--%	-	-	29.31K
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.20%	-0.59%	+52.63%	+128.54%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+56.96%	+138.26%

Neuropathix, Inc. Stock

Stocks

NPTX

US64132Q1094

Biotechnology & Medical Research

Latest news: Neuropathix, Inc.

Press Releases: Neuropathix, Inc.

Managers and Directors: Neuropathix, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile